QQQ   294.25 (+0.30%)
AAPL   148.70 (+0.45%)
MSFT   255.77 (+0.25%)
META   121.03 (+2.48%)
GOOGL   101.27 (+0.28%)
AMZN   95.49 (-1.09%)
TSLA   194.37 (-0.17%)
NVDA   172.33 (+1.83%)
NIO   12.12 (-5.16%)
BABA   86.42 (-1.30%)
AMD   77.56 (-0.09%)
T   19.17 (-0.57%)
MU   55.69 (-3.40%)
CGC   3.86 (+6.63%)
F   14.09 (+1.37%)
GE   85.45 (-0.60%)
DIS   98.71 (+0.86%)
AMC   8.46 (+17.01%)
PYPL   78.50 (+0.11%)
PFE   51.10 (+1.93%)
NFLX   318.93 (+4.39%)
QQQ   294.25 (+0.30%)
AAPL   148.70 (+0.45%)
MSFT   255.77 (+0.25%)
META   121.03 (+2.48%)
GOOGL   101.27 (+0.28%)
AMZN   95.49 (-1.09%)
TSLA   194.37 (-0.17%)
NVDA   172.33 (+1.83%)
NIO   12.12 (-5.16%)
BABA   86.42 (-1.30%)
AMD   77.56 (-0.09%)
T   19.17 (-0.57%)
MU   55.69 (-3.40%)
CGC   3.86 (+6.63%)
F   14.09 (+1.37%)
GE   85.45 (-0.60%)
DIS   98.71 (+0.86%)
AMC   8.46 (+17.01%)
PYPL   78.50 (+0.11%)
PFE   51.10 (+1.93%)
NFLX   318.93 (+4.39%)
QQQ   294.25 (+0.30%)
AAPL   148.70 (+0.45%)
MSFT   255.77 (+0.25%)
META   121.03 (+2.48%)
GOOGL   101.27 (+0.28%)
AMZN   95.49 (-1.09%)
TSLA   194.37 (-0.17%)
NVDA   172.33 (+1.83%)
NIO   12.12 (-5.16%)
BABA   86.42 (-1.30%)
AMD   77.56 (-0.09%)
T   19.17 (-0.57%)
MU   55.69 (-3.40%)
CGC   3.86 (+6.63%)
F   14.09 (+1.37%)
GE   85.45 (-0.60%)
DIS   98.71 (+0.86%)
AMC   8.46 (+17.01%)
PYPL   78.50 (+0.11%)
PFE   51.10 (+1.93%)
NFLX   318.93 (+4.39%)
QQQ   294.25 (+0.30%)
AAPL   148.70 (+0.45%)
MSFT   255.77 (+0.25%)
META   121.03 (+2.48%)
GOOGL   101.27 (+0.28%)
AMZN   95.49 (-1.09%)
TSLA   194.37 (-0.17%)
NVDA   172.33 (+1.83%)
NIO   12.12 (-5.16%)
BABA   86.42 (-1.30%)
AMD   77.56 (-0.09%)
T   19.17 (-0.57%)
MU   55.69 (-3.40%)
CGC   3.86 (+6.63%)
F   14.09 (+1.37%)
GE   85.45 (-0.60%)
DIS   98.71 (+0.86%)
AMC   8.46 (+17.01%)
PYPL   78.50 (+0.11%)
PFE   51.10 (+1.93%)
NFLX   318.93 (+4.39%)
NASDAQ:AKRO

Akero Therapeutics - AKRO Stock Forecast, Price & News

$46.03
-0.47 (-1.01%)
(As of 12/1/2022 03:09 PM ET)
Add
Compare
Today's Range
$45.76
$46.62
50-Day Range
$25.91
$46.50
52-Week Range
$7.52
$48.24
Volume
17,725 shs
Average Volume
525,676 shs
Market Capitalization
$2.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.75

Akero Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2.8% Downside
$44.75 Price Target
Short Interest
Healthy
8.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
1.43mentions of Akero Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$12.07 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.25) to ($3.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

847th out of 1,047 stocks

Pharmaceutical Preparations Industry

414th out of 512 stocks

AKRO stock logo

About Akero Therapeutics (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Stock News Headlines

Recap: Akero Therapeutics Q3 Earnings
Akero Therapeutics Recent Insider Activity
Akero Therapeutics: A Promising NASH Innovator
Akero Therapeutics: Outstanding Data In NASH
What Are Whales Doing With Akero Therapeutics
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Company Calendar

Last Earnings
11/04/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.75
High Stock Price Forecast
$64.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
-2.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-100,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.35 per share

Miscellaneous

Free Float
41,909,000
Market Cap
$2.15 billion
Optionable
Not Optionable
Beta
-0.91

Key Executives

  • Dr. Andrew Cheng M.D. (Age 55)
    Ph.D., Pres, CEO & Director
    Comp: $882.76k
  • Dr. Jonathan M. Young J.D. (Age 52)
    Ph.D., Co-Founder, Exec. VP, COO & Sec.
    Comp: $599.89k
  • Dr. Timothy Rolph (Age 68)
    Co-Founder & Chief Scientific Officer
    Comp: $599.89k
  • Mr. William R. White J.D. (Age 49)
    Exec. VP, CFO, Treasurer & Head of Corp. Devel.
    Comp: $593.27k
  • Ms. Catriona YaleMs. Catriona Yale (Age 50)
    Exec. VP & Chief Devel. Officer
    Comp: $562.39k
  • Mr. John J. Schembri (Age 60)
    VP of Fin. & Controller













AKRO Stock - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price forecast for 2023?

3 brokerages have issued twelve-month price targets for Akero Therapeutics' stock. Their AKRO share price forecasts range from $25.00 to $64.00. On average, they predict the company's share price to reach $44.75 in the next year. This suggests that the stock has a possible downside of 3.8%.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2022?

Akero Therapeutics' stock was trading at $21.15 at the start of the year. Since then, AKRO stock has increased by 119.9% and is now trading at $46.50.
View the best growth stocks for 2022 here
.

Are investors shorting Akero Therapeutics?

Akero Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 4,070,000 shares, a drop of 12.5% from the October 31st total of 4,650,000 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is presently 2.7 days.
View Akero Therapeutics' Short Interest
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Friday, November, 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.19.

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.02%), Vanguard Group Inc. (3.72%), Price T Rowe Associates Inc. MD (3.13%), Atlas Venture Life Science Advisors LLC (2.13%), RA Capital Management L.P. (2.05%) and Marshall Wace LLP (1.61%). Insiders that own company stock include Andrew Cheng, Apple Tree Partners Iv, LP, Catriona Yale, Global Strategic Fund I Venbio, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Timothy Rolph and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $46.50.

How much money does Akero Therapeutics make?

Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $2.17 billion. The company earns $-100,780,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com.

This page (NASDAQ:AKRO) was last updated on 12/1/2022 by MarketBeat.com Staff